Answers are grounded in this paper and cite their sources.
Oral roxadustat was noninferior to parenteral epoetin alfa as therapy for anemia in Chinese patients undergoing dialysis. (Funded by FibroGen and FibroGen [China] Medical Technology Development; ClinicalTrials.gov number, NCT02652806.).
No takes yet. Share an insight, caveat, or question.
Chen et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: